Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Medivir AB ( (SE:MVIR) ).
Medivir AB will present at the Redeye Fight Cancer Event 2026 on January 21, where CEO Jens Lindberg will outline plans for a randomized, controlled phase II-style study evaluating its liver-targeted drug candidate fostrox in combination with lenvatinib versus lenvatinib alone in second-line liver cancer. The live-broadcast presentation underscores Medivir’s strategic emphasis on advancing fostrox as a differentiated treatment option in liver oncology, a move that could strengthen the company’s position in high-unmet-need cancer segments and provide important clinical validation for investors and partners if the study demonstrates superior efficacy.
The most recent analyst rating on (SE:MVIR) stock is a Buy with a SEK54.00 price target. To see the full list of analyst forecasts on Medivir AB stock, see the SE:MVIR Stock Forecast page.
More about Medivir AB
Medivir AB is a Swedish pharmaceutical company listed on Nasdaq Stockholm’s Small Cap list that develops innovative cancer drugs targeting areas of high unmet medical need. Its primary focus is on fostroxacitabine bralpamide (fostrox), a liver-targeted cancer therapy designed to selectively attack cancer cells in the liver while minimizing side effects, often pursued through collaborations and partnerships.
Average Trading Volume: 1,228,545
Technical Sentiment Signal: Sell
Current Market Cap: SEK228.8M
For a thorough assessment of MVIR stock, go to TipRanks’ Stock Analysis page.